Edgewise Therapeutics, Inc. (EWTX) Analyst Estimates Annual - Discounting Cash Flows
EWTX
Edgewise Therapeutics, Inc.
EWTX (NASDAQ)
Period Ending: 2029
12-31
2028
12-31
2027
12-31
2026
12-31
2025
12-31
2024
12-31
Number of Analysts 3 7 10 6 0 0
Estimated Revenue
Low 462.6 167.2 29.37 2.27 0 0
Average 462.6 167.2 29.37 2.27 0 0
High 462.6 167.2 29.37 2.27 0 0
Estimated EBITDA
Low 0 0 0 0 0 0
Average 0 0 0 0 0 0
High 0 0 0 0 0 0
Estimated EBIT
Low 0 0 0 0 0 0
Average 0 0 0 0 0 0
High 0 0 0 0 0 0
Estimated Net Income
Low 37.63 -186.4 -252.3 -211.1 -152.1 -149
Average 37.63 -167.1 -235.3 -173.2 -148.4 -140.5
High 37.63 -74 -123.8 -135.3 -144.7 -131.9
Estimated SGA Expenses
Low 0 0 0 0 0 0
Average 0 0 0 0 0 0
High 0 0 0 0 0 0
Estimated EPS
Low 0.407 -2.02 -2.73 -2.28 -1.65 -1.61
Average 0.407 -1.37 -2.01 -1.94 -1.6 -1.49
High 0.407 -0.801 -1.34 -1.46 -1.57 -1.43
discounting cash flows home logo

Discounting Cash Flows

Are you finding our services helpful? Review us on trustpilot logo Trustpilot
Have a question? Contact us
Want to become our sponsor?
Check out our Affiliate Program